Benitec Biopharma Crecimiento futuro

Future controles de criterios 0/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Benitec Biopharma de 36% y 65% respectivamente, mientras que el BPA crecerá en un 53.7% al año.

Información clave

30.6%

Tasa de crecimiento de los beneficios

52.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.5%
Tasa de crecimiento de los ingresos	68.2%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	27 Sep 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable

Nov 30

We Think Benitec Biopharma (NASDAQ:BNTC) Needs To Drive Business Growth Carefully

Sep 30

Will Benitec Biopharma (NASDAQ:BNTC) Spend Its Cash Wisely?

May 12

Benitec Bio secures $13M capital via equity offering

Apr 28

Can Benitec Biopharma (NASDAQ:BNTC) Afford To Invest In Growth?

Jan 27

How Does Benitec Biopharma's (NASDAQ:BNTC) CEO Salary Compare to Peers?

Dec 02

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:BNTC - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2027	N/A	-60	-5	N/A	2
6/30/2026	N/A	-37	-17	N/A	3
6/30/2025	N/A	-26	-29	N/A	4
6/30/2024	N/A	-22	-20	-19	N/A
3/31/2024	0	-22	-20	-20	N/A
12/31/2023	0	-22	-18	-18	N/A
9/30/2023	0	-20	-19	-19	N/A
6/30/2023	0	-20	-18	-18	N/A
3/31/2023	0	-20	-19	-19	N/A
12/31/2022	0	-19	-18	-18	N/A
9/30/2022	0	-18	-16	-16	N/A
6/30/2022	0	-18	-16	-16	N/A
3/31/2022	0	-17	-16	-16	N/A
12/31/2021	0	-18	-15	-15	N/A
9/30/2021	0	-16	-15	-15	N/A
6/30/2021	0	-14	-13	-13	N/A
3/31/2021	0	-13	-11	-11	N/A
12/31/2020	0	-11	-10	-10	N/A
9/30/2020	0	-10	-10	-9	N/A
6/30/2020	0	-8	-8	-8	N/A
3/31/2020	1	-7	-6	-6	N/A
12/31/2019	1	-6	N/A	N/A	N/A
9/30/2019	7	-2	2	2	N/A
6/30/2019	12	3	4	5	N/A
3/31/2019	12	2	4	4	N/A
12/31/2018	12	2	N/A	N/A	N/A
9/30/2018	8	-3	-3	-3	N/A
6/30/2018	3	-9	-7	-7	N/A
3/31/2018	4	-9	N/A	-7	N/A
12/31/2017	6	-7	N/A	-5	N/A
9/30/2017	5	-7	N/A	-5	N/A
6/30/2017	9	-4	N/A	-6	N/A
3/31/2017	7	-7	N/A	-6	N/A
12/31/2016	7	-8	N/A	-10	N/A
9/30/2016	7	-12	N/A	-13	N/A
6/30/2016	3	-18	N/A	-15	N/A
3/31/2016	3	-18	N/A	-17	N/A
12/31/2015	2	-16	N/A	-14	N/A
9/30/2015	2	-12	N/A	-10	N/A
6/30/2015	3	-9	N/A	-7	N/A
3/31/2015	3	-6	N/A	-5	N/A
12/31/2014	1	-7	N/A	-7	N/A
9/30/2014	1	-7	N/A	-8	N/A
6/30/2014	1	-7	N/A	-9	N/A
3/31/2014	1	-5	N/A	-8	N/A
12/31/2013	1	-3	N/A	-6	N/A
9/30/2013	1	-3	N/A	-5	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que BNTC siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que BNTC siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que BNTC siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que BNTC no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que BNTC no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de BNTC se prevé que sea elevada dentro de 3 años.

Benitec Biopharma Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-Dose BB-301 in Phase 1b/2a Study

Benitec Biopharma Inc. Announces Appointment of Kishen Mehta to Its Board of Directors

Third quarter 2024 earnings released: US$1.64 loss per share (vs US$2.67 loss in 3Q 2023)

Benitec Biopharma Inc. announced that it has received $40.000019 million in funding from a group of investors

New major risk - Share price stability

Benitec Biopharma Inc. Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study

New minor risk - Share price stability

Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable

Benitec Biopharma Announces First Subject Dosed in Phase 1B/2A Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy

New major risk - Financial position

Benitec Biopharma Inc., Annual General Meeting, Dec 06, 2023

Full year 2023 earnings released: US$14.12 loss per share (vs US$37.88 loss in FY 2022)

Benitec Biopharma Regains Compliance with the Bid Price Rule

Benitec Biopharma Provides Nasdaq Compliance Update

New major risk - Share price stability

Insufficient new directors

Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program

Benitec Biopharma Inc., Annual General Meeting, Dec 07, 2022

Benitec Biopharma prices of $18M securities offering

Benitec Biopharma Receives Letter from the Listing Qualifications Department of the Nasdaq Stock Market for Compliance with the Minimum Bid Price Requirement

Full year 2022 earnings: EPS and revenues miss analyst expectations

Benitec GAAP EPS of -$2.23, revenue of $0.07M

Third quarter 2022 earnings released: US$0.40 loss per share (vs US$0.82 loss in 3Q 2021)

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

We're A Little Worried About Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Rate

First quarter 2022 earnings released: US$0.62 loss per share (vs US$2.45 loss in 1Q 2021)

We Think Benitec Biopharma (NASDAQ:BNTC) Needs To Drive Business Growth Carefully

Full year 2021 earnings released: US$3.23 loss per share (vs US$8.10 loss in FY 2020)

Benitec Biopharma Inc. Provides Overview of the BB-301 Phase 1B/2A Clinical Trial Design for 2022

Third quarter 2021 earnings released: US$0.82 loss per share (vs US$1.96 loss in 3Q 2020)

Will Benitec Biopharma (NASDAQ:BNTC) Spend Its Cash Wisely?

Benitec Bio secures $13M capital via equity offering

New 90-day low: US$2.59

Benitec Biopharma Inc. Announces the Successful Results of the Interim Analysis of the Bb-301 Pilot Dosing Study

New 90-day high: US$4.71

Can Benitec Biopharma (NASDAQ:BNTC) Afford To Invest In Growth?

New 90-day high: US$3.88

New 90-day high: US$3.34

How Does Benitec Biopharma's (NASDAQ:BNTC) CEO Salary Compare to Peers?

First quarter 2021 earnings released: US$2.45 loss per share

New 90-day low: US$2.76

New 90-day low: US$4.79

Full year earnings released - US$8.10 loss per share

New 90-day low - US$6.68

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento